165 related articles for article (PubMed ID: 36628536)
1. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
Pfeiffer T; Tzannou I; Wu M; Ramos C; Sasa G; Martinez C; Lulla P; Krance RA; Scherer L; Ruderfer D; Naik S; Bocchini C; Fraser IP; Patel B; Ward D; Wang T; Heslop HE; Leen AM; Omer B
Clin Cancer Res; 2023 Jan; 29(2):324-330. PubMed ID: 36628536
[TBL] [Abstract][Full Text] [Related]
2. Final Outcomes from a Phase 2 Trial of Posoleucel in Allogeneic Hematopoietic Cell Transplant Recipients.
Dadwal SS; Bansal R; Schuster M; Yared JA; Myers GD; Matzko ME; Adnan S; McNeel D; Ma J; Gilmore SA; Vasileiou S; Leen AM; Hill JA; Young JA
Blood Adv; 2024 Apr; ():. PubMed ID: 38593233
[TBL] [Abstract][Full Text] [Related]
3. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients.
Vasileiou S; Kuvalekar M; Velazquez Y; Watanabe A; Leen AM; Gilmore SA
Cytotherapy; 2024 Mar; ():. PubMed ID: 38597860
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT
Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288
[TBL] [Abstract][Full Text] [Related]
6. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
7. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
[TBL] [Abstract][Full Text] [Related]
8. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
9. Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients.
Walti CS; Stuehler C; Palianina D; Khanna N
Curr Opin Infect Dis; 2022 Aug; 35(4):302-311. PubMed ID: 35849520
[TBL] [Abstract][Full Text] [Related]
10. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
11. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: Α prospective single-center study.
Tsoumakas K; Giamaiou K; Goussetis E; Graphakos S; Kossyvakis A; Horefti E; Mentis A; Elefsiniotis I; Pavlopoulou ID
Transpl Infect Dis; 2019 Aug; 21(4):e13095. PubMed ID: 30993823
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and outcome of concurrent and sequential multiviral cytomegalovirus, Epstein-Barr virus, BK virus, adenovirus and other viral reactivations in transplantation.
Sim BZ; Yong KY; Slavin MA; Yong MK
Curr Opin Infect Dis; 2022 Dec; 35(6):536-544. PubMed ID: 36255049
[TBL] [Abstract][Full Text] [Related]
15. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD; Lutzko C; Leemhuis T; Zhu X; Pham G; Ray L; Thomas S; Dourson C; Wilhelm J; Lane A; Cancelas JA; Lipps D; Ferrell J; Hanley PJ; Keller MD; Bollard CM; Wang YM; Davies SM; Nelson AS; Grimley MS
Blood Adv; 2022 May; 6(9):2897-2907. PubMed ID: 35108727
[TBL] [Abstract][Full Text] [Related]
16. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD; Hanley PJ; Chi YY; Aguayo-Hiraldo P; Dvorak CC; Verneris MR; Kohn DB; Pai SY; Dávila Saldaña BJ; Hanisch B; Quigg TC; Adams RH; Dahlberg A; Chandrakasan S; Hasan H; Malvar J; Jensen-Wachspress MA; Lazarski CA; Sani G; Idso JM; Lang H; Chansky P; McCann CD; Tanna J; Abraham AA; Webb JL; Shibli A; Keating AK; Satwani P; Muranski P; Hall E; Eckrich MJ; Shereck E; Miller H; Mamcarz E; Agarwal R; De Oliveira SN; Vander Lugt MT; Ebens CL; Aquino VM; Bednarski JJ; Chu J; Parikh S; Whangbo J; Lionakis M; Zambidis ET; Gourdine E; Bollard CM; Pulsipher MA
Nat Commun; 2024 Apr; 15(1):3258. PubMed ID: 38637498
[TBL] [Abstract][Full Text] [Related]
17. Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation.
Lee SS; Ahn JS; Jung SH; Ahn SY; Kim JY; Jang HC; Kang SJ; Jang MO; Yang DH; Kim YK; Lee JJ; Kim HJ
Korean J Intern Med; 2015 Mar; 30(2):212-8. PubMed ID: 25750563
[TBL] [Abstract][Full Text] [Related]
18. Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States.
Ison MG; Marty FM; Chao N; Moon SH; Zhang Z; Chandak A
Transpl Infect Dis; 2022 Aug; 24(4):e13866. PubMed ID: 35598293
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of viral infections and hemorrhagic cystitis in hematopoietic stem cell transplant recipients.
Shakiba E; Yaghobi R; Ramzi M
Exp Clin Transplant; 2011 Dec; 9(6):405-12. PubMed ID: 22142049
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients.
Coomes EA; Wolfe Jacques A; Michelis FV; Kim DDH; Thyagu S; Viswabandya A; Lipton JH; Messner HA; Deotare U
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1901-1905. PubMed ID: 29679772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
